Sunshine Biopharma Inc. (SBFM): auditor change — Sunshine Biopharma dismisses Bush & Associates, appoints M&K CPAS as auditor effective Sept 24, 2025

Sunshine Biopharma Inc.

Dismissed Bush & Associates CPA LLC as independent auditor on Sept 24, 2025; no prior disagreements or reportable events.
Retained M&K CPAS, PLLC as new independent registered public accounting firm effective same date.
Audit reports for fiscal years 2023 and 2024 were unqualified; no adverse opinions or modifications.
Company requested Bush & Associates to provide letter agreeing with disclosures; letter not yet received, will be filed by amendment.
Change approved by board and audit committee; no consultations with M&K prior to engagement.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Sunshine Biopharma Inc. engaged M&K CPAS, PLLC as its auditor.

Action: engagement
Auditor: M&K CPAS, PLLC

Exact text from the filing

ublic accounting firm and retained M&K CPAS, PLLC (“M&K”) as its independent auditor. The decision to dismiss Bush & Associates and retain M&K was approved by the unanimous consent of the Company’s board of directors and the Company’s

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Sunshine Biopharma Inc. dismissed Bush & Associates CPA LLC as its auditor.

Action: dismissal
Auditor: Bush & Associates CPA LLC
Successor: M&K CPAS, PLLC

Exact text from the filing

Effective September 24, 2025, Sunshine Biopharma Inc. (the “Company”), dismissed Bush & Associates CPA LLC (“Bush & Associates”), as its independent registered public accounting firm and retained M&K CPAS, PLLC (“M&K”) as its independent auditor.

View on SEC.gov

Browse all auditor changes →

Sunshine Biopharma Inc. filing history →

Source: SEC EDGAR

accession 0001683168-25-007338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.